772 Long-Term Mucosal Healing, Clinical Response and Clinical Remission in Patients With Ulcerative Colitis Treated With the Anti-MAdCAM-1 Antibody Ontamalimab: Results From the Open-Label Extension Study TURANDOT II
Silvio Danese(IRCCS Ospedale San Raffaele), Séverine Vermeire(KU Leuven), Walter Reinisch(Medical University of Vienna), Dino Tarabar(Military Medical Academy), Caleb Bliss(Takeda (United States)), William J. Sandborn(University of San Diego), Martina Goetsch(Pfizer (United States)), Tomáš Vaňásek, Fabio Cataldi(Pfizer (United States)), Xavier Hébuterne(Université Côte d'Azur), Paul Hellstern(Clinical Research Atlanta), Miles Sparrow(Alfred Health), Joo Sung Kim(National University College), Charu Gupta(Cytel (United States)), Kenneth J. Gorelick, Miloš Greguš, Maria Kłopocka(Nicolaus Copernicus University)
Cited by 1
Related Papers
STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD
|Gastroenterology|2021|2.6k
Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease
|Nature Genetics|2008|2.6k
Crohn's disease
|The Lancet|2012|2.1k
Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target
|The American Journal of Gastroenterology|2015|1.8k
Serious Infections and Mortality in Association With Therapies for Crohn’s Disease: TREAT Registry
|Clinical Gastroenterology and Hepatology|2006|906